Treatment with an IL-4Rα antagonist or anti-IL-4 neutralizing antibody enhanced the antitumor efficacy of standard drugs and confirmed the autocrine mechanism of IL-4 in CSCs in colon cancer [31]. The gene discussed is IL4; the disease is malignant colon neoplasm.